Skip to main content

Table 3 Multivariate analyses in patients for which data on total nucleated cell counts (TNC) and HLA compatibility were available (n = 363, including 87 male patients given female UCB) (significant factors are in italic)

From: Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood—a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation

Logistic regression

P

OR

95 % CI

AGVH II+

Female to male

0.07

1.7

1.0

3.0

 

Age (years)

0.60

1.0

1.0

1.0

 

Status at Tx

    
 

CR1 versus CR2

0.07

0.6

0.3

1.0

 

CR1 versus advanced

0.04

0.5

0.2

1.0

 

ATG

0.02

0.5

0.3

0.9

 

RIC

0.20

1.5

0.8

2.9

 

Sec AML

0.59

0.8

0.4

1.7

 

Infused cells >2.7 (median)

0.25

0.7

0.5

1.2

 

Nr mism >1

0.70

1.1

0.7

1.8

AGVH III–IV

Female to male

0.06

2.0

1.0

3.9

 

Age (years)

0.90

1.0

1.0

1.0

 

Status at Tx

    
 

CR1 versus CR2

0.38

0.7

0.3

1.5

 

CR1 versus advanced

0.05

0.4

0.1

1.0

 

ATG

0.03

0.5

0.2

0.9

 

RIC

0.80

1.1

0.5

2.6

 

Sec AML

0.56

1.3

0.6

3.0

 

Infused cells >2.7 (median)

0.99

1.0

0.5

1.9

 

Nr mism >1

0.84

0.9

0.5

1.8

Cox models

P

HR

95 % CI

NRM

Female to male

0.06

1.5

1.0

2.2

 

Age (years)

0.21

1.0

1.0

1.0

 

Status at Tx

    
 

CR1 versus CR2

0.01

0.5

0.3

0.8

 

CR1 versus advanced

0.62

0.9

0.5

1.5

 

ATG

0.04

1.5

1.0

2.4

 

RIC

0.09

0.6

0.4

1.1

 

Sec AML

0.06

1.6

1.0

2.4

 

Infused cells >2.7 (median)

0.18

0.8

0.5

1.1

 

Nr mism >1

0.18

0.8

0.5

1.1

RI

Female to male

0.40

1.2

0.8

1.9

 

Age (years)

0.03

1.0

1.0

1.0

 

Status at Tx

    
 

CR1 versus CR2

<10–4

0.2

0.1

0.4

 

CR1 versus advanced

<10–4

0.3

0.2

0.5

 

ATG

0.88

1.0

0.6

1.5

 

RIC

0.04

1.7

1.0

2.9

 

sec AML

0.00

0.2

0.1

0.4

 

Infused cells > 2.7 (median)

0.06

0.7

0.5

1.0

 

Nr mism > 1

0.64

0.9

0.6

1.4

LFS

Female to male

0.04

1.4

1.0

1.9

 

Age (years)

0.03

1.0

1.0

1.0

 

Status at Tx

    
 

CR1 versus CR2

<10–4

0.4

0.3

0.5

 

CR1 versus advanced

0.01

0.6

0.4

0.9

 

ATG

0.14

1.3

0.9

1.7

 

RIC

0.90

1.0

0.7

1.5

 

Sec AML

0.17

0.8

0.5

1.1

 

Infused cells >2.7 (median)

0.04

0.7

0.6

1.0

 

Nr mism >1

0.23

0.8

0.6

1.1

OS

Female to male

0.06

1.3

1.0

1.8

 

Age (years)

0.01

1.0

1.0

1.0

 

Status at Tx

    
 

CR1 versus CR2

<10–4

0.4

0.3

0.5

 

CR1 versus advanced

0.01

0.6

0.4

0.9

 

ATG

0.23

1.2

0.9

1.7

 

RIC

0.35

0.8

0.6

1.2

 

Sec AML

0.35

0.8

0.6

1.2

 

Infused cells >2.7 (median)

0.05

0.8

0.6

1.0

 

Nr mism >1

0.40

0.9

0.7

1.2

  1. HR hazard ratio, CI confidence interval, P P value, AGVHD II+ grades II–IV acute GVHD, AGVHD III–IV grades III–IV acute GVHD, cGVHD cumulative incidence of chronic graft-versus-host disease, NRM cumulative incidence of nonrelapse mortality, RI cumulative incidence of relapse, LFS leukemia-free survival, OS overall survival, Tx transplantation, CR complete remission, advanced not in complete remission, ATG anti-thymocyte globulin, RIC reduced-intensity conditioning, sec AML secondary acute myeloid leukemia
Back to article page